BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 16, 2017
View Archived Issues
miR-651 and miR-708 identified as serum biomarkers of renal cell carcinoma
Read More
Ebselen proves to be safe and effective in preventing noise-induced hearing loss in phase II study
Read More
Galantamine has beneficial effects in subjects with metabolic syndrome
Read More
Takeda Pharmaceutical presents novel mGluR7 agonists
Read More
Shanghai Institute of Organic Chemistry identifies novel IDO-1 inhibitors
Read More
Vitae Pharmaceuticals divulges new nuclear receptor ROR-gamma modulators
Read More
Novel apoptosis regulator Bcl-2 inhibitors patented by Newave Pharmaceutical
Read More
GlaxoSmithKline identifies novel ingenol derivatives
Read More
Luc Therapeutics initiates preclinical development in Ataxia program
Read More
Anti-TNF therapy corrects dysregulation of the Th17:Treg cell axis in hidradenitis suppurativa
Read More
Portola Pharmaceuticals is assigned a PDUFA date for the factor Xa inhibitor antidote andexanet
Read More
Takeda Pharmaceutical and Stanford University in partnership to accelerate therapeutic discoveries
Read More
Israel Innovation Authority grants USD 2 million to Biotime to develop OpRegen
Read More
Abbott extends tender offer for all outstanding shares of preferred stock of Alere
Read More
Lipocine's Tlando receives PDUFA date from the FDA
Read More
Regeneron plans to discontinue development of suptavumab for RSV
Read More
First patient treated in phase II trial of ONC-201 in neuroendocrine tumors
Read More
Soligenix receives additional NIAID funding for the development of heat stable ricin vaccine
Read More
HitGen enters collaboration agreement with Aduro Biotech
Read More
IND application accepted for glioblastoma multiforme immunotherapy VBI-1901
Read More
Shuttle Pharmaceuticals and POLA Pharma enter agreement to licence U.S. rights to doranidazole
Read More
Cerecor sells rights to CERC-501 to Janssen Pharmaceuticals
Read More
NIH awards millions to pediatric cancer research collective
Read More
Evotec announces completion of acquisition of Aptuit
Read More
Phase III study of Fovista in wet age-related macular degeneration does not meet primary endpoint
Read More
Bristol-Myers Squibb announces topline data from CheckMate214 phase III study
Read More
Zynerba Pharmaceuticals presents phase II results for ZYN-002
Read More
Amarin continues the REDUCE-IT cardiovascular outcomes study of Vascepa as planned
Read More
Fortress Biotech launches a new subsidiary to develop gene therapy
Read More
FDA removes clinical hold on phase III trial of Multikine in head and neck cancer
Read More